Free Trial
→ THE NEXT GREAT FINANCIAL CRISIS (it’s already here) (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SRZN

Surrozen Q3 2026 Earnings Date & Estimates

Surrozen logo
$29.69 +1.72 (+6.15%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$30.27 +0.58 (+1.96%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Surrozen is scheduled to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Surrozen in Q3 2026

Surrozen is expected to post earnings of -$1.1039 per share on revenue of $0.48 million. In the same quarter a year earlier Surrozen reported -$3.61 per share on revenue of $0.98 million. Surrozen last reported on August 6, 2026, posting -$0.41 per share and beating the -$1.29 consensus estimate. Surrozen has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.1039
Expected Revenue
$0.48 million
Prior-Year EPS
-$3.61
Prior-Year Revenue
$0.98 million
Expected Revenue Growth
-51.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.41 (Beat by +$0.88)
Last Quarter Revenue
$5.00 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Surrozen Q3 2026 Earnings FAQ

Surrozen (NASDAQ:SRZN) is scheduled to report Q3 2026 earnings on Friday, November 6, 2026, before market opens.

Surrozen's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Surrozen to post earnings of -$1.1039 per share for Q3 2026.

The consensus revenue estimate for Surrozen is $0.48 million for Q3 2026.

Surrozen Earnings Headlines

Financial Contrast: Surrozen (NASDAQ:SRZN) vs. Halozyme Therapeutics (NASDAQ:HALO)
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082854
Surrozen to Advance Potential Eye Drug into Clinical Development Following FDA Clearance
October 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/surrozen-advance-potential-eye-drug-125655316.html
No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
October 10 at 1:00 AM  |  Stansberry Research (Ad)
Surrozen's SZN-8141 IND Cleared By FDA For Diabetic Macular Edema
October 2, 2026  |  rttnews.comhttps://www.rttnews.com/3696162/surrozen-s-szn-8141-ind-cleared-by-fda-for-diabetic-macular-edema.aspx
Surrozen advances diabetic macular edema candidate into clinic after IND clearance
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/surrozen-advances-diabetic-macular-edema-candidate-into-clinic-after-ind-clearance/ar-AA2dquiF
Surrozen Wins FDA IND Clearance for SZN-8141 Program
October 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surrozen-wins-fda-ind-clearance-for-szn-8141-program?utm_source=marketbeat.com&utm_medium=referral
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN) is a clinical-stage biotechnology company focused on developing medicines that selectively activate the Wnt signaling pathway, which plays an important role in tissue repair, regeneration and maintenance. The company uses proprietary antibody-based technologies designed to stimulate Wnt signaling in specific tissues while limiting potential effects elsewhere in the body.

Surrozen’s pipeline has included SZN-1326, an investigational Wnt pathway activator being developed for inflammatory bowel diseases such as ulcerative colitis, and SZN-413, an investigational therapy targeting the FZD4 Wnt signaling pathway for retinal vascular diseases. The company’s programs are intended to address conditions in which impaired tissue repair or abnormal vascular biology contributes to disease.

Founded in 2015 and headquartered in South San Francisco, California, Surrozen has focused primarily on research and clinical development rather than commercialized products. Its therapies remain investigational and are subject to clinical testing and regulatory review; the company does not currently market an approved product.

View Surrozen Profile
Earnings Tools